U.S. Health Secretary Robert F. Kennedy Jr. emphasized during an interview on Fox News’ Special Report with Bret Baier that the Trump administration has no plans to restrict access to vaccines. Kennedy clarified that Americans who want vaccines will continue to have them, countering concerns about possible changes to national health policy.
Addressing recent speculation, Kennedy underscored that the administration supports medical freedom while maintaining access to essential healthcare. He stated that while the government may evaluate certain programs, it will not remove the option for citizens who choose vaccination. This assurance comes at a time when vaccine policy remains a sensitive and highly debated topic in the U.S.
Kennedy’s remarks are intended to reassure families, healthcare providers, and public health advocates who fear potential shifts in vaccine distribution. He noted that the government recognizes the importance of vaccines in preventing disease outbreaks and protecting vulnerable populations. At the same time, the administration aims to respect individual choice, striking a balance between public health priorities and personal freedoms.
The Health Secretary’s statement aligns with broader efforts to ensure transparency and trust between the government and the public. By directly addressing concerns on a national platform, Kennedy sought to reaffirm that vaccines will remain readily available for those who want them, without interference or restriction.
As debates over vaccine policy continue, Kennedy’s comments highlight the administration’s commitment to both accessibility and choice, assuring Americans that their healthcare decisions will remain in their own hands.


Israel Eyes Litani River as New Border Amid Escalating Lebanon Offensive
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
U.S. Deploys Elite 82nd Airborne Troops to Middle East Amid Iran Tensions
Trump Administration Opens Two New Investigations Into Harvard Over Discrimination and Antisemitism
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes
New Zealand Tightens Immigration Laws to Combat Crime and Asylum Abuse
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
ICE Arrest of Guatemalan Woman at San Francisco Airport Sparks Outrage
FCC Approves $3.54B Nexstar-Tegna Merger, Waiving Broadcast Ownership Cap
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology
Pakistan's Diplomatic Rise: Mediating U.S.-Iran Peace Talks
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 



